Fintel reports that on January 8, 2025, TD Cowen upgraded their outlook for Sana Biotechnology (NasdaqGS:SANA) from Hold to Buy.
Analyst Price Forecast Suggests 518.18% Upside
As of December 23, 2024, the average one-year price target for Sana Biotechnology is $10.20/share. The forecasts range from a low of $8.08 to a high of $15.75. The average price target represents an increase of 518.18% from its latest reported closing price of $1.65 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Sana Biotechnology is 0MM. The projected annual non-GAAP EPS is -1.95.
What is the Fund Sentiment?
There are 341 funds or institutions reporting positions in Sana Biotechnology. This is an decrease of 4 owner(s) or 1.16% in the last quarter. Average portfolio weight of all funds dedicated to SANA is 0.07%, an increase of 13.64%. Total shares owned by institutions increased in the last three months by 7.63% to 169,603K shares. 
The put/call ratio of SANA is 0.29, indicating a bullish outlook.
What are Other Shareholders Doing?
Flagship Pioneering holds 25,002K shares representing 11.20% ownership of the company. No change in the last quarter.
Baillie Gifford holds 10,278K shares representing 4.60% ownership of the company. In its prior filing, the firm reported owning 10,571K shares , representing a decrease of 2.85%. The firm decreased its portfolio allocation in SANA by 28.84% over the last quarter.
Canada Pension Plan Investment Board holds 10,175K shares representing 4.56% ownership of the company. No change in the last quarter.
FDGRX - Fidelity Growth Company Fund holds 8,681K shares representing 3.89% ownership of the company. In its prior filing, the firm reported owning 7,017K shares , representing an increase of 19.17%. The firm decreased its portfolio allocation in SANA by 4.55% over the last quarter.
SMCWX - SMALLCAP WORLD FUND INC holds 5,879K shares representing 2.63% ownership of the company. In its prior filing, the firm reported owning 5,881K shares , representing a decrease of 0.04%. The firm decreased its portfolio allocation in SANA by 28.57% over the last quarter.
Sana Biotechnology Background Information
(This description is provided by the company.)
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. Sana shares a vision of repairing and controlling genes, replacing missing or damaged cells, and making its therapies broadly available to patients. Sana is more than 250 people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, and South San Francisco.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
